Predicting Prostate Cancer Progression at Time of Diagnosis
Technical Report,15 Jun 2014,14 Jun 2015
The Regents of the University of California, San Francisco San Francisco United States
Pagination or Media Count:
The goal of this project is to develop a multi-source biomarker panel based on blood obtained prior to surgery and tumor tissue from men undergoing radical prostatectomy for clinically low risk prostate cancer with known pathologic outcome information. In aim 1, the marker panel will be assessed for its ability to predict upgrading and upstaging between biopsy and pathology at prostatectomy. In Aim 2 we will assess the performance of a multi-source biomarker panel derived from blood, urine, and tissue among men accrued to an existing active surveillance cohort. In this aim, the marker panel will be tested for prediction of progression, specifically the extent to which the panel can add independent prognostic information to standard clinical variables. We have made progress toward the stated goals of the project over the past year. We have completed accession and processing of 397 blood specimens from UCSF Aim 1. Tissue analyses are ongoing for DNA and RNA assessments for UCSF patients. We are negotiating a regulatory issue for the Univ. of Washington specimens. Substantial quality of life surveys have been processed for Aim 2, and will be included in the multivariate analyses with the biomarkers. We look forward to completing our analyses and reporting results in the next year.